Graf Acquisition
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch GFOR and buy or sell other stocks, ETFs, and their options commission-free!About GFOR
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression.
CEOPaul Y. Song, MD, PhD
CEOPaul Y. Song, MD, PhD
Employees26
Employees26
HeadquartersSanta Ana, California
HeadquartersSanta Ana, California
Founded
Founded
Employees26
Employees26
GFOR Key Statistics
Market cap3.08M
Market cap3.08M
Price-Earnings ratio-0.04
Price-Earnings ratio-0.04
Dividend yield—
Dividend yield—
Average volume467.89
Average volume467.89
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$0.91
52 Week high$0.91
52 Week low$0.0002
52 Week low$0.0002
Stock Snapshot
Graf Acquisition(GFOR) stock is priced at $0.06, giving the company a market capitalization of 3.08M. It carries a P/E multiple of -0.04.
On 2026-01-21, Graf Acquisition(GFOR) shares started trading at —, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 467.89.
The stock's 52-week range extends from a low of $0.00 to a high of $0.91.
The stock's 52-week range extends from a low of $0.00 to a high of $0.91.
People also own
Based on the portfolios of people who own GFOR. This list is generated using Robinhood data, and it’s not a recommendation.